Oct 30, 2026 earnings call — Specialty pharmacy and provider growth
BrightSpring reported total company revenue of $4.2 billion and adjusted EBITDA of $228 million in Q3.
Revenue $4.2B (est $3.9B) · EPS $0.54 (est $0.47) · Next-quarter revenue outlook $15.9B–$16.1B
Key quotes
"We launched 7 LDDs in the quarter, for a total of 19 year-to-date and we are now supporting 162 total LDDs across dozens of manufacturers and indications."
"Home health care reported $288 million in revenue, growing 50% versus last year, with revenue performance driven by average daily census growth, de novo expansion, and the acquired Amedisys/LHC branches, which contributed $76 million of revenue in the quarter."
"Total adjusted EBITDA is now expected to be in the range of $850 million to $860 million for the full year 2026."
Analyst Q&A 17
what drove gross profit per script
Q (Whit Mayo · Leerink Partners): What caused the change in gross profit per script this quarter and how do you balance gross profit dollars and EBITDA vs per script? Also, what percent of scripts are from home and community pharmacy?
A: Mix was the main driver this quarter, with higher growth in specialty and infusion scripts which have higher gross profit per script. Management is focused on gross profit dollars and EBITDA dollar growth rather than per-script alone. They said they have not disclosed the exact percentage, but a vast majority of scripts are home and community pharmacy.
"From a quarter over quarter perspective, mix was the most significant driver as it relates to the quarter over quarter growth." — Jennifer A. Phipps (CFO)
early performance of a new therapy
Q (Joanna · BofA): How is the early launch trajectory for the Revolution Medicines therapy and did it contribute meaningfully in September? How big a tailwind might it be into 2027?
A: They do not comment on individual drugs or therapies. Management said 2026 launches overall are performing well and are outperforming 2025 launches so far, and they remain excited about future years given the pipeline.
"So we do not comment at the individual drug or therapy level." — Jon Rousseau
why specialty scripts grew 29%
Q (Charles Rhyee · TD Cowen): Is the 29% specialty script growth driven by LDD launches and is that pace sustainable given the LDD wins you announced?
A: They noted provider growth was 30%, slightly higher than specialty, and that specialty growth aligns with their multi-year track record and strategy. Regarding timing, lead time can vary by drug but typically starts at least a year in advance.
"Yeah, 1 thing I would note is, despite the 29% growth rate that you referenced, it was lower than our provider growth rate of 30%." — Jon Rousseau
M&A pipeline and deal types
Q (Albert Rice · UBS): With leverage below target, how do you view the M&A pipeline, deal size appetite, and would you consider partnering with PE? Also, which service lines see more acquisition opportunities?
A: They see a strong M&A platform and interesting opportunities given their balance sheet, focusing mainly on tuck-ins and slightly larger deals within an EBITDA range they described. They have not entertained partnership deals with others and expect to remain deliberate and intentional in transactions while staying balanced across service lines.
"When you couple our capabilities in M&A and our track record, and results there, with the balance sheet It obviously does create interesting opportunities in scenarios." — Jon Rousseau
drivers of 2027 growth mix
Q (Ann Hynes · Mizuho): Does your 2027 outlook imply LDDs are a bigger driver than generics, and what are the long-term growth views for LDDs vs generics?
A: They declined to add to their prepared remarks on 2027 and pointed to those prepared comments. Management said the company has many growth drivers across service lines and expects broad-based growth to continue.
"I think at this time, we are gonna leave our comments regarding 2027 exactly to what we said in the prepared remarks." — Jon Rousseau
infusion competition and capacity
Q (Erin Wilson Wright · Morgan Stanley): Does a recent infusion transaction change the competitive landscape, do you have capacity to support growth, and how is the IG Connect program contributing?
A: They see no change to their strategy and continue to build infusion capacity. Their strategy spans acute and chronic infusion in home and suites, they view acute as an important market, and they are early in the opportunity with meaningful growth expected next year and beyond.
"We do not see any difference to our strategy from that transaction." — Jon Rousseau
home and community pharmacy recovery
Q (Scott Fidel · Goldman Sachs): Post-IRA headwinds and customer exits, what is the underlying growth in home and community pharmacy and how will mix affect GP per script as it returns to growth?
A: They are pleased with the home and community pharmacy performance and said it has become a meaningful contributor again after operational improvements. IRA was and will be a headwind, but they are demonstrating growth and expect significant growth next year if they annualize the recent quarter, while continuing to invest in operational and tech improvements.
"We have been really pleased to see the home and community pharmacy performance this year." — Jon Rousseau
new ACO primary care plan
Q (David Michael Larsen · BTIG): You mentioned joining a next-gen REACH ACO; how do you differentiate, and what revenue/earnings could come near-term and longer-term?
A: They were approved for the next-gen REACH ACO starting January 1 and view primary care as the linchpin between pharmacy and provider services to enable integrated care. They expect meaningful economics could appear around 2028 as the program ramps and shared savings models develop.
"We view primary care is the tip of the spear and the linchpin for integrated care within our company." — Jon Rousseau
specialty competitive position
Q (Matthew Dale Gillmor · KeyBanc): How do you view your competitive position with prescribers and manufacturers as networks narrow and rivals win more exclusives; any notable changes?
A: They see a fairly consistent competitive landscape and emphasize building track record, infrastructure, scale, clinical and technology capabilities to provide value-add services. They continue to evolve and try to improve efficiency and solutions year over year.
"So I think we just continue to evolve our business and try to get a little bit better every year." — Jon Rousseau
hospice and senior living scripts
Q (Raj Kumar · Stephen): Can you quantify script growth across assisted living and hospice, and do you capture hospice patients from your provider side or is that still early?
A: They serve all of their hospice patients with their pharmacy and said their hospice pharmacy business is high quality with strong clinical tools; senior living is also differentiated and both markets are doing well, with continued growth expected.
"On hospice, we serve all of our hospice patients with our pharmacy." — Jon Rousseau
LDD economics over time
Q (Pito Chickering · Deutsche Bank): Have LDD economics changed as you gained market dominance and wraparound services grew—do margins rise from prior 1.5% assumptions?
A: They see stability in GP per script and GP dollars per script over time and have broadened beyond oncology into other indications. They said wraparound services have grown significantly and could be much larger in the next year or two, but overall economics remain consistent.
"In our GP per script and in GP dollars, per script, I think stability is a really appropriate word." — Jon Rousseau
hospital vs retail split for exclusives
Q (Brian Gil Tanquilut · Jefferies): Is the 50% hospital channel estimate still valid for exclusives and where do hospitals source those drugs?
A: Their market data supports a roughly 50/50 hospital split, which can vary by drug. Hospitals either go direct to manufacturers or use other purchasing options when sourcing those drugs.
"The 50 percent estimation is what we see when we look at the market data as well." — Jon Rousseau
corporate SG&A and operating leverage
Q (Jared Haas · William Blair): Why did corporate SG&A fall sequentially and where are efficiencies coming from? What incremental opportunity exists in Q4 and beyond?
A: They continue to leverage corporate infrastructure while investing in technologies, AI products, and people across quality and sales. They expect to remain able to leverage infrastructure for efficiency while making strategic investments that can move G&A quarter to quarter.
"We continue to see the ability to leverage our corporate infrastructure while continuing to invest in new technologies, in AI products, and people across quality sales, and other investment opportunity areas for us." — Jennifer A. Phipps (CFO)
MA contracts and home health programs
Q (Sean Dodge · BMO): What proportion of home health volume is under preferred MA contracts and how much runway exists to add more? What rate differential can you negotiate?
A: Their MA/Medicare mix is similar to some prior public peers and they focus on quality programs that deepen contracts with plans. They see improving rates on the MA side, strong demand for home health, and differentiated offerings like meds in home and virtual primary care that improve outcomes and reduce rehospitalizations.
"I would say, you know, our mix of MA and Medicare is probably not going to be too dissimilar from you know, some of the recent but no longer existing public companies." — Jon Rousseau
operating cash flow drivers and conversion
Q (Parker · Raymond James): What drove the strong operating cash flow this quarter and how should we model cash conversion of adjusted EBITDA going forward?
A: Q3 and Q4 are typically their largest cash flow quarters due to timing and seasonality; working capital benefited from timing of receivables and payables with some one-time elements. They reaffirmed they expect greater than 60% conversion of adjusted EBITDA to operating cash flow on average and noted higher conversion this year excluding community living taxes.
"I would say, you know, generally, across a quarter, what we said at Investor Day would still hold that on average, we would expect to have greater than 60% conversion of adjusted EBITDA to operating cash flow." — Jennifer A. Phipps (CFO)
AI and tech investments update
Q (Jason Cassorla · Guggenheim): Update on AI and tech investments: what returns have you realized so far and what is expected the rest of this year and into next year?
A: They have started many AI and tech implementations in Q3 and Q4 and expect ROI opportunities from them. More of the implemented work should be realized in 2027, they will continue investing in 2027, and see continued growth into 2028 and 2029.
"We have begun many of those and started to implement those into Q3 and Q4." — Jennifer A. Phipps (CFO)
payer mix shift to commercial
Q (Stephen Baxter · Wells Fargo): Why has commercial been driving a larger share of revenue growth this year in specialty and infusion, and how does that affect margins?
A: They said the shift is primarily due to growth in branded LDDs, which are a mix of Medicare and commercial and often served by 1 or 2 pharmacies, and infusion growth is more commercial. Also, expanding into rare and orphan indications can skew more commercial, and they have deepening commercial partnerships in oncology as well.
"Yes, it is primarily associated with growth in branded LDDs." — Jennifer A. Phipps (CFO)